Trial Profile

A Multicenter Open-Label Extension Study to Evaluate the Long-Term Safety of Cenobamate Adjunctive Therapy in Subjects With Primary Generalized Tonic-Clonic Seizures

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cenobamate (Primary)
Indications Generalised seizures; Tonic-clonic epilepsy
Focus Adverse reactions; Registrational
Sponsors SK Life Science

Most Recent Events

13 Dec 2024 Planned End Date changed from 1 Nov 2025 to 1 Aug 2026.
13 Dec 2024 Planned primary completion date changed from 1 May 2025 to 1 Aug 2026.
27 Feb 2024 Planned End Date changed from 1 Nov 2023 to 1 Nov 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com